OSE Immunotherapeutics (XPAR:OSE) Tariff Resilience Score: 0/10 (As of Jul. 13, 2026)


XPAR:OSE OSE Immunotherapeutics SA XPAR:OSE
44 GF Score
Price €3.32
GF Value €1.48
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Tariff Resilience Score?

OSE Immunotherapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

OSE Immunotherapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes OSE Immunotherapeutics might have .

OSE Immunotherapeutics  (XPAR:OSE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

OSE Immunotherapeutics Tariff Resilience Score Related Terms

XPAR:OSE
44GF Score
OSE Immunotherapeutics SA XPAR:OSE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OSE Immunotherapeutics (XPAR:OSE) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.32 is trading 124.5% above its estimated GF Value™ of €1.48. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:OSE:

  • Tariff Resilience Score: 0
  • GF Value™: €1.48 vs. price of €3.32 (124.5% above fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the XPAR:OSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Other Exchanges ORPOF:USA0RAD:UK6OP:Germany
Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
44GF Score

Get the complete analysis for XPAR:OSE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price
€1.48
GF Value